Pipeline

Our broad and versatile set of proprietary platform technologies has allowed us to develop a deep pipeline of wholly-owned, novel product candidates, initially focused on the treatment of hematological malignancies and solid tumors, then in vivo programs for and liver-directed gene therapies for rare diseases.